Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Table 1 Final therapeutic decision at visit 2 based on disease activity control and serum trough infliximab concentration

		Control of disease activity
		Optimal	Acceptable	Inadequate
Infliximab trough concentration	High: C (μg/mL) ≥8.0	Decrease infliximab dosage	Maintain same infliximab dosage	Switch to another biopharmaceutical
	Medium: 2.0 ≤ C (μg/mL) <8.0	Maintain same infliximab dosage	Consider increasing infliximab dosage^a
	Low: C (μg/mL) <2.0		Increase infliximab dosage

Infliximab dosage could not be increased if the current dosage was considered maximal (that is, at least 7.5 mg/kg or interval of not more than 4 weeks). ^aIf the physician kept the same infliximab dosage, another therapeutic intervention could be added (that is, intra-articular corticosteroid injection, physical treatment, or analgesic pharmaceuticals). C, concentration.

ISSN: 1478-6362